CAMBO-VIP for advanced diffuse large cell lymphoma (LSG classification)--a long-term follow-up study

• Published in: Gan to kagaku ryoho Vol. 21; no. 1; p. 67
• Main Authors: Okamoto, M, Maruyama, F, Tsuzuki, M, Nomura, T, Miyazaki, H, Wakita, M, Kojima, H, Sobue, R, Matsui, T, Ino, T
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.01.1994
• Subjects: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bleomycin - administration & dosage; Bleomycin - adverse effects; Bone Marrow - drug effects; Cyclophosphamide - administration & dosage; Cyclophosphamide - adverse effects; Doxorubicin - administration & dosage; Doxorubicin - adverse effects; Drug Administration Schedule; Etoposide - administration & dosage; Etoposide - adverse effects; Female; Follow-Up Studies; Humans; Ifosfamide - administration & dosage; Ifosfamide - adverse effects; Liver - drug effects; Lymphoma, Large B-Cell, Diffuse - drug therapy; Male; Methotrexate - administration & dosage; Methotrexate - adverse effects; Middle Aged; Prognosis; Remission Induction; Vincristine - administration & dosage; Vincristine - adverse effects
• ISSN: 0385-0684

Twenty-two patients with advanced diffuse large cell lymphoma (LSG classification) were treated with the combination chemotherapy of cyclophosphamide, doxorubicin, methotrexate with leucovorin rescue, bleomycin, vincristine, etoposide, ifosfamide and prednisolone (CAMBO-VIP) from Oct. 1987 to Sept. 1989. Eighteen (90%) of 20 evaluable patients achieved complete remission and 2 patients had partial remission. With a median follow-up of 52 mos, 3 patients relapsed (17%), and 2 patients died. The actuarial overall survival and relapse-free survival at 4 years were estimated to be 90% and 83%, respectively. Myelosuppression was severe, but transient. No serious infection was seen, and no platelet transfusion was required. Oral mucositis and liver damage (Grade 3 in WHO grading) was seen in one patient each, but no treatment-related fatalities were observed. CAMBO-VIP is a well tolerated, effective treatment regimen for advanced diffuse large cell lymphoma.